[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Adcendo ApS\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":91},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,40,62],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100620843","phase-1-first-in-human-study-of-adce-b05-in-patients-with-advanced-solid-tumors-100620843",false,"NCT07362888","First-in-Human Study of ADCE-B05 in Patients With Advanced Solid Tumors","A First-in-Human, Phase 1a\u002F1b, Open-Label Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of the Antibody Drug Conjugate ADCE-B05 in Patients With Advanced Solid Tumors","Inclusion Criteria:\n\n* Histologically or cytologically confirmed diagnosis of solid tumor\n* Advanced disease (i.e., unresectable locally advanced or metastatic) and refractory to, intolerant of, or ineligible for approved therapies\n* Radiologically or clinically determined progressive disease during or after most recent line of therapy\n* Measurable disease per RECIST 1.1\n* ECOG performance status of 0 or 1\n* Adequate hematological and biochemical parameters\n* A male patient must agree to use barrier contraception during the treatment period and for at least 4 months after the last infusion of study treatment, and refrain from donating sperm during this period. Male patients with a pregnant partner must practice sexual abstinence or use a barrier method of contraception (e.g., condom) to prevent exposure of the fetus or neonate\n* A female patient who is not pregnant, not breast feeding, and either not a woman of childbearing potential (WOCBP) or agrees to follow the contraceptive guidance during the treatment period and for at least 7 months after last infusion of study treatment\n\nExclusion Criteria\n\n* Treatment with systemic anticancer therapy, including any investigational agent within 3 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration\n* Prior treatment with an ADC containing a topoisomerase I inhibitor payload\n* Primary brain malignancy or known, untreated central nervous system (CNS) or leptomeningeal metastases, or symptoms suggesting CNS involvement for which treatment is required\n* Other malignancy\n* Major surgical procedure or significant traumatic injury within 28 days prior to study drug administration\n* Ongoing systemic infection requiring treatment with antibiotics, antivirals, or antimycotics, other than prophylactic treatment\n* Persistent toxicities from previous systemic anti-neoplastic treatments of Grade \\>1\n* Clinically significant cardiovascular disease\n* Acute infection with human immunodeficiency virus (HIV)-1 or HIV-2\n* Current active liver disease due to hepatitis B or hepatitis C\n* History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis or pulmonary lymphangitic carcinomatosis","ALL","18 Years",{"count":19,"type":20},180,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the Recommended Expansion Dose and the safety and tolerability of ADCE-B05 when given as a single therapy over a range of different dose levels.",[26],"Solid Tumors (Phase 1)","RECRUITING","2026-07-01",{"date":30,"type":31},"2026-07-02","ACTUAL",{"date":33,"type":31},"2026-03-17",{"date":35,"type":20},"2029-03-14",{"name":37,"class":38},"Adcendo ApS","INDUSTRY",7,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":50,"conditions":51,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":61},"100562019","phase-1-adce-t02-a-tissue-factor-targeted-antibody-drug-conjugate-in-patients-with-selected-advanced-solid-tumours-100562019","NCT06597721","ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours","First-in-Human, Phase 1 Study of ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors","Key Inclusion Criteria:\n\n1. Patients must have pathologically confirmed unresectable advanced solid tumor\n2. Patients who have undergone at least one systemic therapy and have progressive disease\n3. Patients must have at least one measurable lesion as per RECIST version 1.1.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.\n5. Life expectancy ≥ 3 months.\n6. Patients must have adequate organ function as indicated by laboratory values\n7. Women of childbearing potential (WCBP), defined as sexually mature women who have not undergone surgical sterilization or who have not been naturally postmenopausal for at least 12 consecutive months must agree to use two effective contraceptive methods while on study treatment and for at least 7 months after the last dose of ADCE T02.\n8. Male patients must agree to use condoms, even if they have had a successful vasectomy, while on study treatment and for at least 4 months after the last dose of ADCE T02.\n\nKey Exclusion Criteria:\n\n1. Prior treatment with any agent targeting Tissue Factor or any ADC with a topoisomerase 1 payload\n2. Central nervous system (CNS) metastasis.\n3. Active ocular surface disease or a history of cicatricial conjunctivitis or inflammatory conditions that predispose to cicatrizing conjunctivitis, mucus pemphigoid or penetrating ocular transplants.\n4. Persistent toxicities from previous systemic anti-neoplastic treatments\n5. Known past or current coagulation defects leading to an increased risk of bleeding\n6. Significant cardiac disease; recent myocardial infarction, acute coronary syndromes, congestive heart failure, uncontrolled hypertension, uncontrolled cardiac arrhythmias\n7. History of (non-infectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids, or current ILD\u002Fpneumonitis, or suspected ILD\u002Fpneumonitis\n8. Prior second malignancy except for:\n\n   * Well treated basal cell carcinoma or squamous cell carcinoma of the skin.\n   * Low-risk prostate cancer with a Gleason score \\\u003C 7 and a PSA level \\\u003C 10 ng\u002FmL\n   * Any cancer or in situ cancer the patient has been disease-free for ≥ 2 years.",{"count":48,"type":20},210,[23],"Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors.\n\nThe main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.",[52],"Advanced Solid Tumor","2026-04-14",{"date":55,"type":31},"2026-04-17",{"date":57,"type":31},"2024-11-25",{"date":59,"type":20},"2026-12-31",{"name":37,"class":38},11,{"id":63,"slug":64,"hasResults":11,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":68,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":70,"targetDuration":4,"studyType":21,"phases":72,"briefSummary":74,"conditions":75,"keywords":78,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},"100577415","phase-1-first-in-human-study-of-adce-d01-in-soft-tissue-sarcoma-100577415","NCT06797999","First-in-Human Study of ADCE-D01 in Soft Tissue Sarcoma","A First-in-human, Phase 1\u002F2, Multicenter, Open-label, Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, and Antitumor Activity of ADCE-D01, a Humanized Anti-human uPARAP Antibody Linked to a Topoisomerase I Inhibitor, in Patients With Metastatic and\u002For Unresectable Soft Tissue Sarcoma","ADCElerate1","Inclusion Criteria:\n\n1. ≥ 18 years of age\n2. Histologically confirmed STS with metastatic and\u002For unresectable disease (not amenable to treatment with curative intent).\n3. Prior treatment with at least one but no more than two lines of cytotoxic systemic therapy for metastatic\u002Funresectable disease.\n4. Measurable disease as per RECIST v 1.1.\n5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n6. Life expectancy of at least 3 months.\n7. A male patient must agree to use barrier contraception during the treatment period and for at least 4 months after the last infusion of study treatment, and refrain from donating sperm during this period. Male patients with a pregnant partner must practice sexual abstinence or use a barrier method of contraception (e.g., condom) to prevent exposure of the fetus or neonate.\n8. A female patient is eligible if not pregnant, not breast feeding, and not a woman of childbearing potential (WOCBP), or agrees to follow the contraceptive guidance during the treatment period and for at least 7 months after last infusion of study treatment.\n\nExclusion Criteria:\n\n1. Patients who have had systemic anticancer therapy, including any investigational agent within 4 weeks or 5 half-lives (whichever is shorter) prior to study treatment administration.\n2. Primary brain malignancy or known, untreated central nervous system (CNS) or leptomeningeal metastases, or symptoms suggesting CNS involvement.\n3. Clinically significant cardiovascular disease\n4. Patients with acute infection with human immunodeficiency virus (HIV) 1 or HIV 2.\n5. Current active liver disease due to hepatitis B\n6. History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on a chest computed tomography (CT) scan at screening.",{"count":71,"type":20},270,[23,73],"PHASE2","The goal of this clinical trial is to learn about the safety, tolerability and efficacy of ADCE-D01.",[76,77],"Metastatic Soft Tissue Sarcoma","Unresectable Soft Tissue Sarcoma",[79,80,81],"Phase 1\u002FPhase 2","Sequential","Treatment","2026-01-27",{"date":84,"type":31},"2026-01-28",{"date":86,"type":31},"2025-06-05",{"date":88,"type":20},"2029-02-27",{"name":37,"class":38},8,""]